MIDD In Early Oncology Clinical Development: Dose Optimization
Dose optimization has become an increasingly challenging, but necessary task as developers explore more next-generation oncology therapies and novel combinations. Find out how model-informed drug development (MIDD) can play an integral role in keeping vital oncology trials on track to deliver life-saving therapies to patients in need.
Get an inside look at:
Whitepaper Clinical Studies Pharmaceutical Research and Development